Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4878439 | 0.86 | P2RX7 (0.67) | P2RX7AVPR1A | |
| SCHEMBL4881070 | 0.84 | P2RX7 (0.79) | P2RX7 | |
| SCHEMBL4883004 | 0.83 | P2RX7 (0.68) | P2RX7 | |
| SCHEMBL4885209 | 0.82 | P2RX7 (0.68) | P2RX7 | |
| SCHEMBL4880412 | 0.82 | P2RX7 (0.68) | P2RX7 | |
| SCHEMBL4880557 | 0.82 | P2RX7 (0.72) | P2RX7 | |
| SCHEMBL4880558 | 0.82 | P2RX7 (0.66) | P2RX7 | |
| SCHEMBL4878448 | 0.82 | P2RX7 (0.66) | P2RX7 | |
| SCHEMBL5119318 | 0.81 | P2RX7 (0.70) | P2RX7 | |
| SCHEMBL7571588 | 0.81 | P2RX7 (1.00) | P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080153850-A1 | Adamantyl Derivates as P2x7 Receptor Antagonists | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | US | claimed |
| US-20080153850-A1 | Adamantyl Derivates as P2x7 Receptor Antagonists | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | US | disclosed |
| US-20080153850-A1 | Adamantyl Derivates as P2x7 Receptor Antagonists | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | US | disclosed |
| US-20080153850-A1 | Adamantyl Derivates as P2x7 Receptor Antagonists | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153850-A1 | Adamantyl Derivates as P2x7 Receptor Antagonists | ADORA1, P2RX1, P2RY1 | P2RX7 4/4885AVPR1A 105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.